Ophidian Pharmaceuticals Inc. has received notification of apatent allowance for its anti-venom techniques.
The privately held Madison, Wisc., company will be issued aU.S. patent, No. 5,196,193, that applies to both composition andmethods for producing antidotes to poisonous animal bites andstings.
Incorporated in December 1989, Ophidian acquired thetechnology from Sean Carroll of the University of Wisconsin,Madison. An antidote for treating poisonous snakebite in theU.S. has received orphan drug status and is the subject of a co-development and license agreement announced last monthbetween Ophidian and the Wyeth-Ayerst Laboratories divisionof American Home Products.
The drug is also being used for poisonous animal bites andseveral forms of food poisoning, including botulism andparalytic shellfish poisoning.
The company is also pursuing broader applications of theunderlying technology, such as the treatment of infectiousdisease. -- Nancy Garcia
(c) 1997 American Health Consultants. All rights reserved.